Patients with advanced head and neck squamous cell carcinoma cancer are needed for a study to research an experimental drug in combination with chemoradiation therapy

IRB/UVA Tracking #
20190
Principal Investigator
Varinder Kaur
Contact
Olusegun Bamidele Adelaja
Contact Email
Contact Phone
804.527.4240
Official Trial Title
A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have advanced head and neck squamous cell carcinoma cancer. The purpose of this study to evaluate the combination of an experimental drug (VX-970) and chemotherapy (cisplatin) with radiation therapy in patients with advanced head and neck squamous cell carcinoma cancer. The study drug dose, safety, and effects of the experimental drug combination will be evaluated for this study. Participation is approximately 2 months of treatment, with an additional 3 months of frequent follow-up visits to keep track of how you are doing. A final 2-year follow-up visit will be done when you come in for your standard of care clinical visit. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT02567422

Compensation

You will not receive compensation for this study.